Antitumor activity of N-(2-hydroxypropyl)methacrylamide copolymer- mesochlorin e6 and Adriamycin conjugates in combination treatments

Clinical Cancer Research

Volumn 6, Issue 3, 2000, Pages 1008-1015

  Shiah, Jane Guo ^a   Sun, Yongen ^c   Peterson, C Matthew ^b   Straight, Richard C ^c   Kopeček, Jindřich ^a  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; COPOLYMER; DOXORUBICIN DERIVATIVE; METHACRYLIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TARGETING; FEMALE; MOUSE; NONHUMAN; OVARY CARCINOMA; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; TUMOR RECURRENCE;

ACRYLAMIDES; ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DOXORUBICIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MESOPORPHYRINS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; WEIGHT LOSS;

EID: 0034059468     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. De Duve, C., De Barsy, T., Poole, B., Trouet, A., Tulkens, P., and van Hoof, F. Lysosomotropic agents. Biochem. Pharmacol., 23: 2495-2531, 1974.
2. Putnam, D., and Kopeček, J. Polymer conjugates with anticancer activity. Adv. Polym. Sci., 122: 55-123, 1995.
3. Vasey, P. A., Kaye, S. B., Morrison, R., Twelves, C., Wilson, P., Duncan, R., Thomson, A. H., Murray, L. S., Hilditch, T. E., Murray, T., Burtles, S., Fraier, D., Frigerio, E., and Cassidy, J. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin. Cancer Res., 5: 83-94, 1999.
4. Thompson, A. H., Vasey, P. A., Murray, L. S., Cassidy, J., Fraier, D., Frigerio, E., and Twelves, C. Population pharmacokinetics in Phase I drug development: a Phase I study of PK1 in patients with solid tumors. Br. J. Cancer, 81: 99-107, 1999.
5. Minko, T., Kopečková, P., and Kopeček, J. Chronic exposure to HPMA copolymer-bound Adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line. J. Controlled Release, 59: 133-148, 1999.
6. Minko, T., Kopečková, P., and Kopeček, J., Efficacy of chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Int. J. Cancer, in press, 2000.
7. Říhová, B. Antibody-targeted polymer-bound drugs. Folia Microbiol., 40: 367-384, 1995.
8. Maeda, H., Seymour, L. M., and Miyamoto, Y. Conjugates of anti-cancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjugate Chem., 3: 351-362, 1992.
9. Noguchi, Y., Wu, J., Duncan, R., Strohalm, J., Ulbrich, K., Alaike, T., and Maeda, H. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res., 89: 307-314, 1998.
10. Fritzberg, A. R. Biorecognition of antibodies in vivo: potential in drug targeting. J. Mol. Recognit., 9: 309-315, 1996.
11. Sjogren, H. O., Isaksson, M., Willner, D., Hellstrom, I., Hellstrom, K. E., and Trail, P. A. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats. Cancer Res., 57: 4530-4536, 1997.
12. 6 immunoconjugates. Biotechnol. Prog., 8: 30-39, 1992.
13. Yarmush, M. L., Thorpe, W. P., Strong, L., Rakestraw, S. L., Toner, M., and Tompkins, R. G. Antibody targeted photolysis. Crit. Rev. Ther. Drug Carrier Syst., 10: 197-252, 1993.
14. Trail, P. A., Willner, D., Lasch, S. J., Henderson, A. J., Hofstead, S., Casazza, A. M., Firestone, R. A., Hellstrom, I., and Hellstrom, K. E. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science (Washington DC), 261: 212-215, 1993.
15. Lu, Z-R., Kopečková, P., and Kopeček, J. Polymerizable Fab′ antibody fragments for targeting of anticancer drugs. Nat. Biotechnol., 17: 1101-1104, 1999.
16. Tolcher, A. W., Sugarman, S., Gelmon, K. A., Cohen, R., Saleh, M., Isaacs, C., Young, L., Healey, D., Onetto, N., and Slichenmyer, W. Randomized Phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J. Clin. Oncol., 17: 478-484, 1999.
17. Markman, M. Basic Cancer Medicine. Philadelphia, PA: W. B. Saunders Company, 1997.
18. Meirow, D. Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radio-chemotherapy for hemato-oncological neoplasias and other cancers. Leuk. Lymphoma, 33: 65-76, 1999.
19. Lidor, Y. L., O'Briant, K. C., Xu, F. J., Hamilton, T. C., Ozols, R. F., and Bast, R. C., Jr. Alkylating agents and immunotoxins exert synergistic cytotoxicity against ovarian cancer cells. J. Clin. Investig., 92: 2440-2447, 1993.
20. Canti, G., Nicolin, A., Cubeddu, R., Taroni, P., Bandieramonte, G., and Valentini, G. Antitumor efficacy of the combination of photodynamic therapy and chemotherapy in murine tumors. Cancer Lett., 125: 39-44, 1998.
21. Brophy, P. F., and Keller, S. M. Adriamycin enhanced in vitro and in vivo photodynamic therapy of mesothelioma. J. Surg. Res., 52: 631-634, 1992.
22. Krinick, N. L., Sun, Y., Joyner, D., Spikes, J. D., Straight, R. C., and Kopeček, J. A polymeric drug delivery system for the simultaneous delivery of drugs activatable by enzymes and/or light. J. Biomater. Sci. Polym. Ed., 5: 303-324, 1994.
23. Peterson, C. M., Lu, J. M., Sun, Y., Peterson, C. A., Shiah, J. G., Straight, R. C., and Kopeček, J. Combination chemotherapy and photodynamic therapy with N-(2-hydroxypropyl)methacrylamide copolymer-bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice. Cancer Res., 56: 3980-3985, 1996.
24. 6 monoethylene diamine induced photodynamic therapy in human epithelial ovarian carcinoma in vitro. Int. J. Oncol., 15: 5-16, 1999.
25. 6 and Adriamycin in nude mice bearing human ovarian carcinoma OVCAR-3 xenografts. J. Controlled Release, 61: 145-157, 1999.
26. Omelyanenko, V., Kopečková, P., Gentry, C., Shiah, J. G., and Kopeček, J. HPMA copolymer-anticancer drug-OV-TL 16 antibody conjugates. I. Influence of the method of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro. J. Drug Targeting, 3: 357-373, 1996.
27. Hashimoto, Y., Hirano, T., and Yamaguchi, N. Novel after-loading interstitial photodynamic therapy of canine transmissible sarcoma with photofrin II and excimer dye laser. Jpn. J. Cancer Res., 86: 239-244, 1995.
28. Takakura, Y., and Hashida, M. Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution. Pharm. Res. (NY), 13: 820-831, 1996.
29. 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in mice with transplanted melanoma and mammary carcinoma. J. Drug Targeting, 3: 375-383, 1996.
30. Seymour, L. W., Ulbrich, K., Strohalm, J., Kopeček, J., and Duncan, R. The pharmacokinetics of polymer-bound Adriamycin. Biochem. Pharmacol., 39: 1125-1131, 1990.
31. Jain, R. K. Delivery of molecular and cellular medicine to solid tumors. Microcirculation, 4: 1-23, 1997.
32. Feng, D., Nagy, J. A., Hipp, J., Dvorak, H. F., and Dvorak, A. M. Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. J. Exp. Med., 183: 1981-1986, 1996.
33. Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., Yancopoulos, G. D., and Wiegand, S. J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science (Washington DC), 284: 1994-1998, 1999.
34. Goff, B. A., Blake, J., Bamberg, M. P., and Hasan, T. Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model. Br. J. Cancer, 74: 1194-1198, 1996.
35. Marecos, E., Weissleder, R., and Bogdanov, A., Jr. Antibody-mediated versus nontargeted delivery in a human small cell lung carcinoma model. Bioconjugate Chem., 9: 184-191, 1998.
36. Andrejevic-Blant, S., Hadjur, C., Ballini, J. P., Wagnieres, G., Fontolliet, C., van-den-Bergh, H., and Monnier, P. Photodynamic therapy of early squamous cell carcinoma with tetra(m-hydroxyphenyl)chlorin: optimal drug-light interval. Br. J. Cancer, 76: 1021-1028, 1997.
37. 6 monoethylene diamine in human epithelial ovarian carcinoma (OVCAR-3) in vitro. J. Soc. Gynecol. Invest., 2: 772-777, 1995.
38. Molpus, K. L., Kato, D., Hamblin, M. R., Lilge, L., Bamberg, M., and Hasan, T. Intraperitoneal photodynamic therapy of human epithelial ovarian carcinomatosis in a xenograft murine model. Cancer Res., 56: 1075-1082, 1996.
39. Colussi, V. C., Feyes, D. K., Mulvihill, J. W., Li, Y. S., Kenney, M. E., Elmets, C. A., Oleinick, N. L., and Mukhtar, H. Phthalocyanine 4 (Pc 4) photodynamic therapy of human OVCAR-3 tumor xenografts. Photochem. Photobiol., 69: 236-241, 1999.
40. Minko, T., Kopečková, P., and Kopeček, J. Comparison of the anticancer effect of free and HPMA copolymer-bound Adriamycin in human ovarian carcinoma cells. Pharm. Res. (NY), 16: 986-996, 1999.
41. Rejmanová, P., Kopeček, J., Duncan, R., and Lloyd, J. B. Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers. Biomaterials, 6: 45-48, 1985.
42. Rejmanová, P., Pohl, J., Baudys, M., Kostka, V., and Kopeček, J. Polymers containing enzymatically degradable bonds 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B. Makromol. Chem., 184: 2009-2020, 1983.
43. Omelyanenko, V., Gentry, C., Kopečková, P., and Kopeček, J. HPMA copolymer-anticancer drug-OV-TL 16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro. Int. J. Cancer, 75: 600-608, 1998.
44. Omelyanenko, V., Kopečková, P., Gentry, C., and Kopeček, J. Targetable HPMA copolymer-Adriamycin conjugates. Recognition, internalization, and subcellular fate. J. Controlled Release, 53: 25-37, 1998.